The New York Times
eGenesis
Restoring life after organ failure.
Our Science
Ending waitlists. Redefining futures.
We are a team of innovators working at the intersection of genome engineering and transplantation. By advancing human-compatible organs for patients with organ failure, eGenesis aims to address the fundamental limitation of donor availability, to eliminate wait lists and remove supply as a determinant of patient outcomes. Our goal is to move transplantation beyond scarcity toward durable, life-saving solutions for patients.
Kidney
High Global Prevalence: Chronic kidney disease affects an estimated 850 million people worldwide, with millions progressing to end-stage kidney disease or kidney failure, requiring dialysis or transplant to survive.
Liver
Growing Disease Burden: Chronic liver disease affects hundreds of millions globally, with tens of thousands of patients each year progressing to liver failure, requiring a transplant for survival.
Heart
Staggering Disease Burden: Heart disease is the leading cause of death, with millions of people globally diagnosed with heart failure across stages of severity. Over 6 million US adults are living with heart failure.
Our Commitment
From lives on hold to futures within reach.
Millions of people in the U.S. suffer from organ failure and could benefit from a life-saving transplant. Xenotransplantation is the key to ending this suffering. Learn more about the difference xenotransplantation is making in everyday lives through the experience of pioneering patients.
FDA Clinical Trials
IND Clearance Marks a Major Milestone.
The U.S. Food and Drug Administration (FDA) has cleared our Investigational New Drug (IND) application to initiate a Phase 1/2/3 trial evaluating EGEN-2784, a genetically engineered porcine-derived kidney, in patients with end-stage kidney disease (ESKD).
Our Breakthrough
A platform that unlocks human compatibility.
By utilizing three classes of edits to address organ safety and efficacy, this integrated approach enables the precise engineering of human-compatible organs to support the advancement of our transplant programs.
In The News
The latest from our media room.
-
-
The Economist
-
CNN